 |
11 Diseases |  |
2 Trials |
|
2 Trials |  |
100 News |  |
| 12» |
- || tenalisib (RP6530) / Rhizen
Enrollment open, Metastases: Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Mar 5, 2024
P2, N=40, Recruiting, Sponsor: Rhizen Pharmaceuticals SA
Not yet recruiting --> Recruiting
- || Istodax (romidepsin) / Astellas, BMS, tenalisib (RP6530) / Rhizen
Clinical, P1/2 data, Journal, Combination therapy: Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study. (Pubmed Central) - Jan 9, 2024
P1/2
Coadministration of tenalisib and romidepsin did not significantly alter the pharmacokinetics of romidepsin. Overall, tenalisib and romidepsin combination demonstrated a favorable safety and efficacy profile supporting its further development for relapsed/refractory TCL.
- || tenalisib (RP6530) / Rhizen
New P2 trial, Metastases: Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Jan 2, 2024
P2, N=40, Not yet recruiting, Sponsor: Rhizen Pharmaceuticals SA
- || tenalisib (RP6530) / Rhizen
Trial completion, Trial completion date, Trial primary completion date, Metastases: Efficacy and Safety of Tenalisib (RP6530), a PI3K ?/? and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - May 17, 2023
P2, N=40, Completed, Sponsor: Rhizen Pharmaceuticals SA
Overall, tenalisib and romidepsin combination demonstrated a favorable safety and efficacy profile supporting its further development for relapsed/refractory TCL. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
- | Istodax (romidepsin) / Astellas, BMS, tenalisib (RP6530) / Rhizen
Journal, Monotherapy: Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory s (Pubmed Central) - May 1, 2023
Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway by Tenalisib presents one such emerging drug. We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monotherapy.
- tenalisib (RP6530) / Rhizen
Efficacy and safety of tenalisib, a PI3K ?/? and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study. (On Demand | Hall A; Poster Bd # 285) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3256;
P2
Updated efficacy and tolerability data will be provided at the time of presentation. Clinical trial information: NCT05021900.
- | CN1 / Curon Biopharma, tenalisib (RP6530) / Rhizen
Enrollment change, Trial completion date, Trial termination, Combination therapy: A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov) - Oct 24, 2022
P1/2, N=7, Terminated, Sponsor: Curon Biopharmaceutical (Australia) Co Pty Ltd
Clinical trial information: NCT05021900. N=78 --> 7 | Trial completion date: Jul 2023 --> Sep 2022 | Recruiting --> Terminated; Sponsor decided that there was no benefit in the drug treatment and due to company change in landscape in the new year.
- | tenalisib (RP6530) / Rhizen
Enrollment change, Trial withdrawal: Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL (clinicaltrials.gov) - Oct 17, 2022
P2, N=0, Withdrawn, Sponsor: Rhizen Pharmaceuticals SA
N=78 --> 7 | Trial completion date: Jul 2023 --> Sep 2022 | Recruiting --> Terminated; Sponsor decided that there was no benefit in the drug treatment and due to company change in landscape in the new year. N=40 --> 0 | Not yet recruiting --> Withdrawn
- | tenalisib (RP6530) / Rhizen
Trial initiation date: Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL (clinicaltrials.gov) - Aug 18, 2022
P2, N=40, Not yet recruiting, Sponsor: Rhizen Pharmaceuticals SA
N=40 --> 0 | Not yet recruiting --> Withdrawn Initiation date: May 2022 --> Jan 2023
- tenalisib (RP6530) / Rhizen
Efficacy and safety of tenalisib, a PI3K delta/gamma and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Results from a phase II study (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2736;
P2
Tenalisib potentiated the activity of fulvestrant by inhibiting cell growth and causing cell cycle arrest in both MCF-7 and ZR.75.1 breast cancer cell lines...Based on the data from the ongoing study, overall efficacy response as a single agent in both primary and secondary resistant MBC continues to be encouraging and supports further development in MBC. Updated efficacy and tolerability data will be presented at the conference.
- | tenalisib (RP6530) / Rhizen
Enrollment closed, Metastases: Efficacy and Safety of Tenalisib (RP6530), a PI3K ?/? and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - May 3, 2022
P2, N=40, Active, not recruiting, Sponsor: Rhizen Pharmaceuticals SA
Updated efficacy and tolerability data will be presented at the conference. Recruiting --> Active, not recruiting
- tenalisib (RP6530) / Rhizen
Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Initial results from a phase II study. (Available On Demand; 437) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1146;
P2
Based on the data from the ongoing study, Tenalisib showed encouraging preliminary efficacy as a single agent in patients with advanced MBC. Updated efficacy and tolerability data will be provided at the time of presentation.
- tenalisib (RP6530) / Rhizen
Efficacy and Safety of Tenalisib, a PI3K _/_ and SIK3 inhibitor in Patients with Locally Advanced or Metastatic Breast Cancer: Initial results from a Phase II study (Exhibition area) - Mar 19, 2022 - Abstract #ESMOBC2022ESMO_BC_380;
P2
Two pts were discontinued due to related AEs (rash and GGT elevation).Conclusions Based on the data from the ongoing study , Tenalisib showed encouraging preliminary efficacy as a single agent in patients with advanced MBC. Updated efficacy and tolerability data will be provided at the time of presentation.
- || tenalisib (RP6530) / Rhizen
New P2 trial: Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL (clinicaltrials.gov) - Feb 15, 2022
P2, N=40, Not yet recruiting, Sponsor: Rhizen Pharmaceuticals SA
- Istodax (romidepsin) / Astellas, BMS, tenalisib (RP6530) / Rhizen
Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_2934;
P1/2
The combination of tenalisib and romidepsin demonstrates a favorable safety profile and promising anti-tumor activity in patients with R/R TCL. Based on these encouraging results, further development of this combination in PTCL patients in being planned.
- ||| tenalisib (RP6530) / Rhizen
Enrollment change, Trial completion date, Trial primary completion date: Compassionate Use Study of Tenalisib (RP6530) (clinicaltrials.gov) - Nov 2, 2021
P1/2, N=17, Enrolling by invitation, Sponsor: Rhizen Pharmaceuticals SA
Based on these encouraging results, further development of this combination in PTCL patients in being planned. N=10 --> 17 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
- || tenalisib (RP6530) / Rhizen
Enrollment open, Metastases: Efficacy and Safety of Tenalisib (RP6530), a PI3K ?/? and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 12, 2021
P2, N=40, Recruiting, Sponsor: Rhizen Pharmaceuticals SA
N=10 --> 17 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Oct 2021 --> Oct 2022 Not yet recruiting --> Recruiting
- || tenalisib (RP6530) / Rhizen
Trial completion, Trial completion date, Combination therapy, Epigenetic controller: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma (clinicaltrials.gov) - Sep 28, 2021
P1/2, N=33, Completed, Sponsor: Rhizen Pharmaceuticals SA
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Nov 2021 --> May 2021
- || tenalisib (RP6530) / Rhizen
New P2 trial, Metastases: Efficacy and Safety of Tenalisib (RP6530), a PI3K ?/? and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 25, 2021
P2, N=40, Not yet recruiting, Sponsor: Rhizen Pharmaceuticals SA
- ||| CN1 / Curon Biopharma, tenalisib (RP6530) / Rhizen
Enrollment open, Combination therapy: A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov) - Aug 24, 2021
P1/2, N=78, Recruiting, Sponsor: Curon Biopharmaceutical (Australia) Co Pty Ltd
Active, not recruiting --> Completed | Trial completion date: Nov 2021 --> May 2021 Not yet recruiting --> Recruiting
- || tenalisib (RP6530) / Rhizen
Clinical, P1 data, Journal: A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. (Pubmed Central) - May 13, 2021
Pharmacodynamics correlated well with clinical outcome. Further phase I/II studies are being undertaken to evaluate efficacy across different histologies.
- |||| CN1 / Curon Biopharma, tenalisib (RP6530) / Rhizen
New P1/2 trial, Combination therapy: A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov) - May 9, 2021
P1/2, N=78, Not yet recruiting, Sponsor: Curon Biopharmaceutical (Australia) Co Pty Ltd
- | tenalisib (RP6530) / Rhizen
Trial primary completion date, Combination therapy, Epigenetic controller: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma (clinicaltrials.gov) - Mar 15, 2021
P1/2, N=42, Active, not recruiting, Sponsor: Rhizen Pharmaceuticals SA
Further phase I/II studies are being undertaken to evaluate efficacy across different histologies. Trial primary completion date: Dec 2020 --> May 2021
- tenalisib (RP6530) / Rhizen
Trial completion date, Trial primary completion date: Compassionate Use Study of Tenalisib (RP6530) (clinicaltrials.gov) - Dec 4, 2020
P1/2, N=10, Enrolling by invitation, Sponsor: Rhizen Pharmaceuticals SA
Trial primary completion date: Dec 2020 --> May 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
- ||| tenalisib (RP6530) / Rhizen
Rhizen Pharma is all set to present at ASH 2020 tomorrow! #ASH20 #Tenalisib (Twitter) - Dec 4, 2020
- | tenalisib (RP6530) / Rhizen
Enrollment closed, Combination therapy, Epigenetic controller: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma (clinicaltrials.gov) - Nov 10, 2020
P1/2, N=42, Active, not recruiting, Sponsor: Rhizen Pharmaceuticals SA
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Oct 2021 Recruiting --> Active, not recruiting
- tenalisib (RP6530) / Rhizen
[VIRTUAL] An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) () - Nov 5, 2020 - Abstract #ASH2020ASH_5258;
Tenalisib showed promising single agent anti-tumor activity in patients with CLL with a favourable safety profile. Further data is awaited to estimate the response rates and the decision to move to Stage 2 of the study.
- Istodax (romidepsin) / Astellas, BMS, tenalisib (RP6530) / Rhizen
[VIRTUAL] A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_928;
P1/2
The expansion cohort in CTCL and PTCL is currently underway to validate these encouraging early results. Updated results will be presented during the ASH meeting.
- ||| tenalisib (RP6530) / Rhizen
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Nov 2, 2020
P2, N=21, Completed, Sponsor: Rhizen Pharmaceuticals SA
Updated results will be presented during the ASH meeting. Recruiting --> Completed | N=61 --> 21 | Trial completion date: Aug 2022 --> Oct 2020 | Trial primary completion date: Dec 2021 --> Oct 2020
- || tenalisib (RP6530) / Rhizen
Trial completion, Trial primary completion date: Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K ?/? Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov) - Oct 19, 2020
P2, N=20, Completed, Sponsor: Rhizen Pharmaceuticals SA
Recruiting --> Completed | N=61 --> 21 | Trial completion date: Aug 2022 --> Oct 2020 | Trial primary completion date: Dec 2021 --> Oct 2020 Active, not recruiting --> Completed | Trial primary completion date: Sep 2020 --> Jun 2020
- | tenalisib (RP6530) / Rhizen
Trial completion date, Trial primary completion date, Combination therapy, Epigenetic controller: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma (clinicaltrials.gov) - Oct 6, 2020
P1/2, N=42, Recruiting, Sponsor: Rhizen Pharmaceuticals SA
Active, not recruiting --> Completed | Trial primary completion date: Sep 2020 --> Jun 2020 Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Aug 2020 --> Dec 2020
- |||||| umbralisib (TGR-1202) / TG Therap, tenalisib (RP6530) / Rhizen
Clinical: $TGTX partner Rhizen (TGTX bought umbralisib from them) Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma @semodough @SagarLonialMD @Pharmdca @pawcio2009 @TGTherapeutics https://t.co/6vf27Ed5Er (Twitter) - Sep 30, 2020
- || tenalisib (RP6530) / Rhizen
Clinical, P1 data, Journal: Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. (Pubmed Central) - Aug 24, 2020
With an acceptable safety and promising clinical activity, Tenalisib can be a potential therapeutic option for relapsed/refractory TCL. Currently, a phase I/II combination study with romidepsin is ongoing.
- | tenalisib (RP6530) / Rhizen
Enrollment closed: Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K ?/? Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov) - Jul 1, 2020
P2, N=20, Active, not recruiting, Sponsor: Rhizen Pharmaceuticals SA
Currently, a phase I/II combination study with romidepsin is ongoing. Recruiting --> Active, not recruiting
- azacitidine / Generic mfg., tenalisib (RP6530) / Rhizen
[VIRTUAL] THERAPEUTIC POTENTIAL OF TENALISIB, A PI3K DELTA/GAMMA PLUS SIK-3 INHIBITOR, IN HEMATOLOGICAL MALIGNANCIES () - May 16, 2020 - Abstract #EHA2020EHA_748;
A Phase 1/2 study evaluating the safety and efficacy of Tenalisib in combination with Romidepsin in relapsed/refractory T-cell lymphoma is currently ongoing in the USA...Cell growth following incubation (72 h) with IN0385 as a single agent or in combination with Azacytidine, or Venetoclax was determined in the AML lines: THP-1, U937, and MV-4-11...Gene expression studies in specific cell types and xenograft models are currently underway to further elucidate the role and utility of IN0385 in other hematological malignancies. A Phase-1 trial in relapsed/refractory AML is planned.
- | tenalisib (RP6530) / Rhizen
Journal, Tumor microenvironment: Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530. (Pubmed Central) - Apr 15, 2020
A Phase-1 trial in relapsed/refractory AML is planned. Our results support PI3Kδ/γ inhibition as a novel therapeutic strategy that targets both malignant cells and the TME to treat HL patients.
- | tenalisib (RP6530) / Rhizen
Trial completion date, Trial primary completion date: Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K ?/? Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov) - Mar 11, 2020
P2, N=20, Recruiting, Sponsor: Rhizen Pharmaceuticals SA
Our results support PI3Kδ/γ inhibition as a novel therapeutic strategy that targets both malignant cells and the TME to treat HL patients. Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Feb 2020 --> Oct 2020
- |||| tenalisib (RP6530) / Rhizen
New P2 trial: Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Dec 17, 2019
P2, N=61, Recruiting, Sponsor: Rhizen Pharmaceuticals SA
- tenalisib (RP6530) / Rhizen
Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_4012;
P1, P1/2
Tenalisib demonstrated promising clinical activity and an improved safety profile in patients with relapsed/ refractory TCL . Currently, a phase I/II combination study to further evaluate safety and efficacy with romidepsin is ongoing in this target population.
- tenalisib (RP6530) / Rhizen
Enrollment status: Compassionate Use Study of Tenalisib (RP6530) (clinicaltrials.gov) - Oct 29, 2019
P1/2, N=10, Enrolling by invitation, Sponsor: Rhizen Pharmaceuticals SA
Currently, a phase I/II combination study to further evaluate safety and efficacy with romidepsin is ongoing in this target population. Recruiting --> Enrolling by invitation
- | Jakafi oral (ruxolitinib) / Novartis, Incyte
Journal: Development of new agents for peripheral T-cell lymphoma. (Pubmed Central) - Jun 9, 2019
In addition, mogamulizumab (anti-CC chemokine receptor 4 antibody), chidamide (histone deacetylase inhibitor), and forodesine (purine nucleoside phosphorylase inhibitor) have been approved in Asian countries, including China, and Japan...However, these are not a curative option when used as a single agent. Further clinical developments are expected, comprising 1) combination therapies of new agents with cytotoxic chemotherapies; 2) "novel-novel" combinations; 3) immune therapies, including chimeric antigen receptor T-cell therapy; and 4) predictive marker analysis.
- || tenalisib (RP6530) / Rhizen
Enrollment open, Combination therapy, Epigenetic controller: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma (clinicaltrials.gov) - Mar 22, 2019
P1/2, N=42, Recruiting, Sponsor: Rhizen Pharmaceuticals SA
Further clinical developments are expected, comprising 1) combination therapies of new agents with cytotoxic chemotherapies; 2) "novel-novel" combinations; 3) immune therapies, including chimeric antigen receptor T-cell therapy; and 4) predictive marker analysis. Not yet recruiting --> Recruiting
- | tenalisib (RP6530) / Rhizen
Trial initiation date, Combination therapy, Epigenetic controller: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma (clinicaltrials.gov) - Feb 26, 2019
P1/2, N=42, Not yet recruiting, Sponsor: Rhizen Pharmaceuticals SA
Not yet recruiting --> Recruiting Initiation date: Dec 2018 --> Mar 2019
- | tenalisib (RP6530) / Rhizen
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL (clinicaltrials.gov) - Feb 26, 2019
P1/2, N=2, Terminated, Sponsor: Rhizen Pharmaceuticals SA
Initiation date: Dec 2018 --> Mar 2019 N=57 --> 2 | Trial completion date: Dec 2019 --> Feb 2019 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Feb 2019; At this point, the current study in HL does not fit into clinical development and regulatory strategy.
- ||| tenalisib (RP6530) / Rhizen
Trial completion: Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma (clinicaltrials.gov) - Dec 13, 2018
P1, N=58, Completed, Sponsor: Rhizen Pharmaceuticals SA
N=57 --> 2 | Trial completion date: Dec 2019 --> Feb 2019 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Feb 2019; At this point, the current study in HL does not fit into clinical development and regulatory strategy. Active, not recruiting --> Completed
- || tenalisib (RP6530) / Rhizen
New P1/2 trial, Combination therapy, Epigenetic controller: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma (clinicaltrials.gov) - Dec 10, 2018
P1/2, N=42, Not yet recruiting, Sponsor: Rhizen Pharmaceuticals SA
- | tenalisib (RP6530) / Rhizen
Enrollment open: Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K ?/? Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov) - Oct 29, 2018
P2, N=20, Recruiting, Sponsor: Rhizen Pharmaceuticals SA
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | tenalisib (RP6530) / Rhizen
New P1/2 trial: Compassionate Use Study of Tenalisib (RP6530) (clinicaltrials.gov) - Oct 18, 2018
P1/2, N=10, Recruiting, Sponsor: Rhizen Pharmaceuticals SA